In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Potential impact of the CMS GENEROUS model
Reference country selection The model provided guidance on reference countries, defined by the G7 countries plus Denmark and Switzerland. Reference...
